Lechleider Robert 4

What Happened

• Robert Lechleider, Chief Medical Officer of Immunome (IMNM), exercised 55,000 option shares on July 2, 2026 at an exercise price of $8.73 per share (cost = $480,150). He then sold 55,000 shares in three open-market tranches (22,714 @ $21.95; 16,214 @ $22.76; 16,072 @ $23.44) for aggregate proceeds of about $1,244,331. The filing also reports a related derivative disposal entry (55,000 at $0.00) tied to the option conversion.

Key Details

• Transaction date: July 2, 2026; Form filed July 7, 2026 (appears after the typical 2-business-day Form 4 deadline).
• Exercise: 55,000 shares exercised at $8.73 each (total cost $480,150).
• Sales: 22,714 shares @ weighted avg $21.95 (range $21.26–$22.25); 16,214 shares @ weighted avg $22.76 (range $22.26–$23.25); 16,072 shares @ weighted avg $23.44 (range $23.26–$23.67). Total proceeds ≈ $1,244,331.
• Post-transaction holdings: Not specified in the provided summary—see the full Form 4 for the insider’s reported beneficial ownership after these transactions.
• Footnotes: Sales were effected under a Rule 10b5-1 trading plan adopted March 26, 2026 (F1). Weighted-average price ranges are provided in footnotes F2–F4; vesting schedule for the option is noted (25% vested Oct 16, 2024; remainder monthly over three years) (F5).
• Timing: Filing date suggests a delayed Form 4 relative to the common 2-business-day filing requirement; investors may want to check the official filing for any timeliness code.

Context

• This was an option exercise followed by immediate sale of the resulting shares (commonly a cashless exercise or sell-to-cover pattern). The combination of an exercised option and contemporaneous open-market sales means the insider converted vested options into cash rather than retaining additional shares.
• The sales were executed under a pre-established 10b5-1 plan, which typically schedules trades in advance and may indicate routine liquidity management rather than a trading decision based on current company developments.